A New Dawn for the Failing Heart: AnaCardio Drug Promises Power Without Peril

STOCKHOLM, Sweden – June 25, 2026 – In the relentless battle against heart failure, a leading cause of death and disability worldwide, a significant new contender has emerged. Stockholm-based biopharmaceutical company AnaCardio today announced that results from its study of AC01, a first-in-class oral drug, have been published in the prestigious medical journal The Lancet. The findings signal a potential paradigm shift in treating heart failure with reduced ejection fraction (HFrEF), a condition where the heart muscle doesn't contract effectively.

The early-stage clinical trial demonstrated that AC01 not only improved the heart’s pumping capacity but did so with a remarkable safety profile, sidestepping the dangerous side effects that have plagued similar-acting drugs for decades. For the millions living under the shadow of HFrEF, this news represents more than just a scientific achievement; it represents a tangible flicker of hope for a safer, more effective chronic therapy.

Rethinking a Decades-Old Dilemma

Heart failure is a deceptive term. It doesn’t mean the heart has stopped, but rather that it’s failing to pump enough blood to meet the body's needs. For patients with HFrEF, the standard of care has evolved into a formidable four-pillar regimen of medications that slow the disease's progression and manage symptoms. While these therapies have saved countless lives, they don't directly address the fundamental mechanical problem: a weakened heart muscle.

For years, the only drugs capable of directly boosting the heart's contractility—known as inotropes—have been a double-edged sword. While they can provide a necessary short-term jolt to a failing heart in a hospital setting, their long-term use is associated with life-threatening arrhythmias, increased oxygen demand on an already-strained heart muscle, and even higher mortality. This has left a gaping hole in the treatment landscape: a safe, oral therapy that patients can take at home to directly and chronically improve their heart’s pumping power.

"Heart failure remains a devastating global health issue... Current treatment options primarily address symptoms and risk factors but fail to target the underlying issue of reduced contractility," one industry analyst noted. AC01 enters this arena with a fundamentally different approach. The drug is what’s known as a calcium-sensitizing agent. Instead of flooding the heart cells with calcium, which can trigger dangerous arrhythmias, it makes the heart muscle more sensitive to the calcium already present. This allows for a stronger contraction without the associated electrical instability. Furthermore, as a ghrelin mimetic, it activates a secondary pathway linked to cardioprotective and metabolic benefits, a dual mechanism that sets it apart.

The Promise of Power Without the Peril

The GOAL-HF1 study, now validated by The Lancet's rigorous peer-review process, provides the first human evidence of this unique mechanism's potential. The Phase 1b/2a trial enrolled 58 patients with HFrEF who were already on optimal modern therapy. The results were striking.

Patients receiving AC01 showed rapid and sustained improvements in key measures of heart function. In the highest dose group, cardiac output—the amount of blood the heart pumps per minute—surged by nearly 30% on the first day and remained elevated a month later. Left ventricular ejection fraction, a core metric of pumping efficiency, saw a mean increase of 4.8 percentage points, a clinically meaningful improvement compared to the 1.6-point increase seen in the placebo group.

More importantly, the drug appeared to be exceptionally safe. The study reported no AC01-related serious adverse events, deaths, or treatment discontinuations. Crucially, there were no signs of the tachycardia, arrhythmias, or myocardial ischemia that have historically made traditional inotropes untenable for chronic use.

"The exploratory efficacy results from GOAL-HF1 are very encouraging, with AC01 showing improvements in cardiac output and multiple measures of cardiac structure and function," commented Professor Lars Lund, a cardiologist at Karolinska University Hospital, founder of AnaCardio, and the publication's lead author. "Importantly, the drug was safe and well tolerated... a profile that stands in marked contrast to the historical limitations of traditional inotropic therapies. Taken together, these findings provide a strong foundation to guide late-stage clinical trials."

From Academic Insight to Clinical Hope

The journey of AC01 is a case study in modern translational medicine, bridging foundational science with patient-focused drug development. AnaCardio was founded on groundbreaking research from Sweden’s renowned Karolinska Institutet, and the company has methodically advanced its lead candidate, which was originally in-licensed from the pharmaceutical group Helsinn.

This scientific rigor has attracted significant financial backing. The privately held firm has raised over USD 40 million to date, with a recent USD 19 million funding round co-led by major international life science investors like Novo Holdings and Pureos Bioventures. This financial stability is buttressed by a robust intellectual property portfolio, with recently issued patents in both the United States and Europe securing market exclusivity for AC01's use in HFrEF until at least 2042.

"Publication of the GOAL-HF1 results in The Lancet is a defining milestone for AnaCardio and represents the highest level of scientific validation we could receive for AC01," said Patrik Strömberg, CEO of AnaCardio. "We believe these results represent an important step forward and support the rapid advancement of AC01 into Phase 2b clinical development."

Navigating the Path to Patients

With positive scientific advice already secured from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), AnaCardio is now preparing to launch a larger Phase 2b study later this year. This next step will be critical in confirming the drug's efficacy and safety in a larger patient population over a longer duration.

The competitive landscape for novel heart failure therapies is dynamic, but AC01 appears to be carving out a unique niche. Other attempts at creating oral contractility enhancers have faced challenges; Cytokinetics' omecamtiv mecarbil, which uses a different mechanism, was rejected by the FDA in 2023. Meanwhile, the most established calcium sensitizer, levosimendan, is administered intravenously for acute care.

AC01's potential as a safe, chronic, oral therapy places it in a class of its own. If its early promise holds true in later-stage trials, it could become a vital new pillar of HFrEF treatment, offering a direct boost to the heart's engine for the first time without the historical baggage of life-threatening risk. For the millions of patients navigating the daily challenges of a weakened heart, that promise is a powerful one.